Synapse Open Synapse
Biology

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

STAT News · · 1 min read

Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.

Latest from STAT News